Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
13 Gennaio 2021 - 3:00PM
Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader
in the growing field of cancer metabolism-based therapeutics, today
announced that Sanjeev Luther, President and Chief Executive
Officer, will present at the virtual 39th Annual J.P. Morgan
Healthcare Conference, on Thursday, Jan. 14.
Mr. Luther will discuss the status of the Company and milestones
it met throughout the year, including receiving two FDA-granted
Fast Track designations for its lead compound CPI-613®
(devimistat), for the treatment of metastatic pancreatic cancer and
the treatment of acute myeloid leukemia (AML). He will also
highlight the most recent trial launches, including a Phase 2
clinical trial for patients with clear cell sarcoma of soft
tissue.
“Rafael has achieved significant milestones in 2020, despite the
unique challenges presented amid the COVID-19 pandemic,” said
Sanjeev Luther, President and CEO of Rafael. “We
are eager to highlight the successes over the past year during the
presentation, as well as discuss the key learnings that we believe
will propel us forward in 2021. It is truly humbling to see how we
continue to come closer to our ultimate goal of treating
hard-to-treat cancers with a novel approach to therapy, cancer
metabolism.”
Presentation Details:Date: Thursday,
Jan. 14, 2021Time: 5:20 p.m. - 6:00 p.m.
ETLocation: Virtual
The presentation will be webcast and accessible for companies
presenting and attending the J.P. Morgan Health Conference. An
archived replay of the presentation will be available on the
Company's website, rafaelpharma.com.
About CPI-613® (devimistat) CPI-613®
(devimistat) is a first-in-class clinical lead compound of Rafael,
which targets enzymes that are involved in cancer cell energy
metabolism and are located in the mitochondria of cancer cells.
Devimistat is designed to target the mitochondrial tricarboxylic
acid (TCA) cycle, a process essential to tumor cell multiplication
and survival, selectively in cancer cells. Devimistat substantially
increases the sensitivity of cancer cells to a diverse range of
chemotherapeutic agents. This synergy allows for potential
combinations of devimistat with lower doses of these generally
toxic drugs to be more effective with lower patient’s side effects.
Combination with devimistat represent a diverse range of
opportunities to substantially improve patient’s benefit in many
different cancers. The U.S. Food and Drug Administration (FDA) has
given Rafael approval to initiate pivotal Phase 3 clinical trials
in pancreatic cancer (AVENGER 500) and acute myeloid leukemia
(ARMADA 2000), and has designated devimistat as an orphan drug for
the treatment of pancreatic cancer, acute myeloid leukemia,
myelodysplastic syndrome, peripheral T-cell lymphoma and Burkitt’s
lymphoma. The EMA has granted orphan drug designation to devimistat
for pancreatic cancer and acute myeloid leukemia.
About Rafael Pharmaceuticals, Inc.Rafael
Pharmaceuticals is a leader in the growing field of cancer
metabolism. The company is developing a new, first-in-class
category of metabolic oncology therapeutics that attack
hard-to-treat cancers by targeting the metabolic processes the
disease needs to survive, grow and proliferate. Rafael
Pharmaceuticals’ lead compound, CPI-613® (devimistat), is a highly
selective, well-tolerated and effective anti-cancer agent that is
being evaluated in ongoing and completed Phase 1, 2 and 3 clinical
trials. Devimistat has been granted orphan drug status by the FDA
for the treatment of pancreatic cancer, acute myeloid leukemia
(AML), myelodysplastic syndrome (MDS) and Burkitt’s, peripheral
T-cell lymphomas and soft tissue sarcoma. The Company's investors
include Rafael Holdings, Inc. (NYSE AMERICAN: RFL). For more
information, please visit www.rafaelpharma.com.
Safe Harbor StatementThis press release
contains forward-looking statements. These statements relate to
future events or the company’s future financial performance. In
some cases, you can identify forward-looking statements by
terminology such as "may", "will", "should", "expect", "plan",
"anticipate", "believe", "estimate", "predict", "potential" or
"continue", the negative of such terms, or other comparable
terminology. These statements are only predictions. Actual events
or results may differ materially from those in the forward-looking
statements as a result of various important factors. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, such statements should not be regarded
as a representation by the company, or any other person, that such
forward-looking statements will be achieved. The business and
operations of the company are subject to substantial risks which
increase the uncertainty inherent in forward-looking statements. We
undertake no duty to update any of the forward-looking statements,
whether as a result of new information, future events or
otherwise.
In light of the foregoing, readers are cautioned not to place
undue reliance on such forward-looking statements.
###
Rafael Media Contact:Vanessa
Donohuerafael@antennagroup.com (201) 465-8036
Grafico Azioni Rafael (AMEX:RFL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Rafael (AMEX:RFL)
Storico
Da Giu 2023 a Giu 2024